** Shares of drugmaker Bristol Myers Squibb BMY.N fall 3.9% to $57.39 premarket
** Co forecasts 2025 revenue of around $45.5 billion, below analysts' average expectation of $47.4 billion - LSEG data
** Sees 2025 EPS between $6.55 and $6.85 per share, below estimates of $6.92
** BMY expects generic competition for some of its older drugs
** Co is expanding its cost-cutting program by additional $2 billion by end of 2027, bringing total cost cuts under the program to $3.5 billion
** Stock rose ~10% in 2024
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.